Success Metrics

Clinical Success Rate
83.3%

Based on 5 completed trials

Completion Rate
83%(5/6)
Active Trials
0(0%)
Results Posted
60%(3 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_1
2
25%
Ph phase_2
4
50%
Ph phase_3
2
25%

Phase Distribution

2

Early Stage

4

Mid Stage

2

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
2(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

71.4%

5 of 7 finished

Non-Completion Rate

28.6%

2 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(5)
Terminated(2)
Other(1)

Detailed Status

Completed5
unknown1
Terminated1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
83.3%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 24 (50.0%)
Phase 32 (25.0%)

Trials by Status

completed563%
unknown113%
terminated113%
withdrawn113%

Recent Activity

0 active trials
Showing 5 of 8
unknownphase_2

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

NCT01811368
completedphase_3

Zevalin-beam for Aggressive Lymphoma

NCT00491491
completedphase_2

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

NCT00662948
terminatedphase_1

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

NCT00372905
completedphase_1

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

NCT00392691
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT01811368Phase 2

Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

Unknown
NCT00491491Phase 3

Zevalin-beam for Aggressive Lymphoma

Completed
NCT00662948Phase 2

ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxetan (Zevalin®) Versus Maintenance Treatment With Rituximab (MabThera®)

Completed
NCT00372905Phase 1

Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

Terminated
NCT00392691Phase 1

Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment

Completed
NCT00453102Phase 2

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma

Completed
NCT00319332Phase 3

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Withdrawn
NCT00193440Phase 2

Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma

Completed

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8